{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:21Z","timestamp":1793968281828,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008670","name":"Terumo Foundation for Life Sciences and Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018627","name":"Research Center Network for Realization of Regenerative Medicine","doi-asserted-by":"publisher","award":["AMED JP21bm0104001"],"award-info":[{"award-number":["AMED JP21bm0104001"]}],"id":[{"id":"10.13039\/100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102976","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:05:48Z","timestamp":1785996348000},"page":"102976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of pluripotent stem cell-derived myeloid line-based chimeric antigen receptor macrophage-like cells identifies limited in vivo persistence"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9088-6724","authenticated-orcid":false,"given":"Yuya","family":"Atsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-2686","authenticated-orcid":false,"given":"Akira","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Kumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yagyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yozo","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8813-3614","authenticated-orcid":false,"given":"Megumu K.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102976_bib0001","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse functions of macrophages in different tumor microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102976_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2026.102976_bib0003","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0006","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2026.102976_bib0007","doi-asserted-by":"crossref","first-page":"1045024","DOI":"10.3389\/fimmu.2023.1045024","article-title":"Bright future or blind alley? CAR-T cell therapy for solid tumors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0008","doi-asserted-by":"crossref","first-page":"100543","DOI":"10.1016\/j.xcrm.2022.100543","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jcyt.2026.102976_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jcyt.2026.102976_bib0010","doi-asserted-by":"crossref","first-page":"1545928","DOI":"10.3389\/fimmu.2025.1545928","article-title":"The mechanism of action and therapeutic potential of tumor-associated macrophages in tumor immune evasion","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0011","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102976_bib0012","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/s12276-023-01068-z","article-title":"A new era of macrophage-based cell therapy","volume":"55","author":"Na","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jcyt.2026.102976_bib0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102976_bib0014","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102976_bib0015","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102976_bib0016","doi-asserted-by":"crossref","first-page":"1238535","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.jcyt.2026.102976_bib0017","first-page":"S243","article-title":"Balancing the CAR T: perspectives on efficacy and safety of CAR T-cell therapy in hematologic malignancies","volume":"27","author":"Buie","year":"2021","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jcyt.2026.102976_bib0018","doi-asserted-by":"crossref","first-page":"1305657","DOI":"10.3389\/fped.2023.1305657","article-title":"Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma","volume":"11","author":"Negishi","year":"2024","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jcyt.2026.102976_bib0019","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13287-024-03785-2","article-title":"Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions","volume":"15","author":"Ackermann","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102976_bib0020","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","article-title":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study","volume":"12","author":"Strati","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0021","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/gt.2012.59","article-title":"TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells","volume":"20","author":"Haruta","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102976_bib0022","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27927","article-title":"Application of iPS cell-derived macrophages to cancer therapy","volume":"3","author":"Senju","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2026.102976_bib0023","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.humimm.2013.05.017","article-title":"Generation of a large number of functional dendritic cells from human monocytes expanded by forced expression of cMYC plus BMI1","volume":"74","author":"Haruta","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152384","article-title":"Generation of large numbers of antigen-expressing human dendritic cells using CD14-ML technology","volume":"11","author":"Imamura","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102976_bib0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2326-6066.CIR-15-0096","article-title":"Immunotherapy against metastatic melanoma with human iPS cell-derived myeloid cell lines producing type I interferons","volume":"4","author":"Miyashita","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102976_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jhbp.422","article-title":"et al.Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-\u03b2","volume":"24","author":"Sakisaka","year":"2017","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jcyt.2026.102976_bib0027","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1111\/cas.13775","article-title":"et al. Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta","volume":"109","author":"Imamura","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jcyt.2026.102976_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067567","article-title":"Therapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-\u03b2 against peritoneally disseminated cancer in xenograft models","volume":"8","author":"Koba","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102976_bib0029","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.stemcr.2018.04.025","article-title":"Generation of TCR-expressing innate lymphoid-like helper cells that induce cytotoxic T cell-mediated anti-leukemic cell response","volume":"10","author":"Ueda","year":"2018","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.jcyt.2026.102976_bib0030","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/mt.2011.131","article-title":"PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor","volume":"19","author":"Nakazawa","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102976_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1175>3.0.CO;2-F","article-title":"MR 77 KDA factor derived from fibroblasts stimulates the invasion ability of breast-cancer cells","author":"Ikeda","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcyt.2026.102976_bib0032","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2019.242693","article-title":"Down syndrome-related transient abnormal myelopoiesis is attributed to a specific erythro-megakaryocytic subpopulation with GATA1 mutation","volume":"106","author":"Nishinaka-Arai","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102976_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247595","article-title":"Pluripotent stem cell model of early hematopoiesis in down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification","volume":"16","author":"Matsuo","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102976_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059243","article-title":"Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions","volume":"8","author":"Yanagimachi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102976_bib0035","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nbt.2931","article-title":"Normalization of RNA-seq data using factor analysis of control genes or samples","volume":"32","author":"Risso","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0036","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0037","doi-asserted-by":"crossref","first-page":"e01563","DOI":"10.1128\/jvi.01563-23","article-title":"Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses","volume":"98","author":"Yang","year":"2024","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0038","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcyt.2026.102976_bib0039","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/01466216221089345","article-title":"Factor retention using machine learning with ordinal data","volume":"46","author":"Goretzko","year":"2022","journal-title":"Appl Psychol Meas"},{"key":"10.1016\/j.jcyt.2026.102976_bib0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto Encyclopedia of Genes and Genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcyt.2026.102976_bib0041","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"ClusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.jcyt.2026.102976_bib0042","article-title":"Chimeric antigen receptor-macrophage therapy enters the clinic: the first-in-human trial for HER2+ solid tumors","volume":"6","author":"Ma","year":"2025","journal-title":"Med Comm"},{"key":"10.1016\/j.jcyt.2026.102976_bib0043","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102976_bib0044","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat Commun"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:22:47Z","timestamp":1793967767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926009370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1465324926009370"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102976","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of pluripotent stem cell-derived myeloid line-based chimeric antigen receptor macrophage-like cells identifies limited in vivo persistence","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102976"}}